Abstract
Protein tyrosine phosphatase 1B (PTP1B) has been implicated as one of the key negative regulators of insulin and leptin signal transduction pathways. PTP1B deficient mice are more sensitive to insulin, and have improved glycemic control and resistance to diet-induced obesity than the wild-type control mice. Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. The rapid development of this field is evidenced by the increasing number of patents and publications in recent years. This review will highlight the recent advances in various approaches for attenuating PTP1B action, particularly small molecule PTP1B inhibitors, and the challenges associated with developing PTP1B inhibitors with drug like properties.
Keywords: insulin resistance, type II diabetes, obesity, protein tyrosine phosphatase, antisense oligonucleotide, phosphotyrosyl mimetics, structure-based drug design, cellular permeability, second phosphotyrosyl binding site
Current Medicinal Chemistry
Title: Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges
Volume: 10 Issue: 15
Author(s): Gang Liu
Affiliation:
Keywords: insulin resistance, type II diabetes, obesity, protein tyrosine phosphatase, antisense oligonucleotide, phosphotyrosyl mimetics, structure-based drug design, cellular permeability, second phosphotyrosyl binding site
Abstract: Protein tyrosine phosphatase 1B (PTP1B) has been implicated as one of the key negative regulators of insulin and leptin signal transduction pathways. PTP1B deficient mice are more sensitive to insulin, and have improved glycemic control and resistance to diet-induced obesity than the wild-type control mice. Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. The rapid development of this field is evidenced by the increasing number of patents and publications in recent years. This review will highlight the recent advances in various approaches for attenuating PTP1B action, particularly small molecule PTP1B inhibitors, and the challenges associated with developing PTP1B inhibitors with drug like properties.
Export Options
About this article
Cite this article as:
Liu Gang, Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges, Current Medicinal Chemistry 2003; 10 (15) . https://dx.doi.org/10.2174/0929867033457296
DOI https://dx.doi.org/10.2174/0929867033457296 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness
Current Pharmaceutical Design Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Development of Conformational Mimetics of Conserved Streptococcus Pyogenes Minimal Epitope as Vaccine Candidates
Current Drug Delivery Environmental Pollution and Diabetes Mellitus
Recent Patents on Biomarkers Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Heme Oxygenase-1 against Vascular Insufficiency: Roles of Atherosclerotic Disorders
Current Pharmaceutical Design Using Properties of Tumor Microenvironments for Controlling Local, On-Demand Delivery from Biopolymer-Based Nanocarriers
Current Pharmaceutical Design Biomarkers in the Diagnosis of Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Successfully Resuscitated Sudden Cardiac Death in a Young Homosexual Male with HIV Myocarditis
Current HIV Research HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry